Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...

The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...

Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive ...

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...

Sanofi has reported positive results from its Phase III HERCULES trial of tolebrutinib for non-relapsing secondary ...